Atlas Trials

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

Clinical trial NCT01885208 · COMPLETED

Trial details

NCT number
NCT01885208
Sponsor
Novo Nordisk A/S
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
DiabetesDiabetes Mellitus, Type 2
Start date
2013-12-02
Primary completion
2015-07-13
Enrollment
813

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.